<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7937731</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">33692747</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">7937731</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.3389/fneur.2021.642241</article-id></all-ids><extracted-table><table-id>T1</table-id><table-label>Table 1</table-label><table-caption>Patients' demographic, clinical, and molecular characteristics of patient population by group.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1</label><caption><p>Patients' demographic, clinical, and molecular characteristics of patient population by group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" colspan="4" style="border-bottom: thin solid #000000;" rowspan="1"><bold>Summary of characteristics</bold></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>Short term survival (</bold><italic><bold>n</bold></italic><bold>=</bold><bold>35)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Long term survival (</bold><italic><bold>n</bold></italic><bold>=</bold><bold>29)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><italic><bold>P</bold></italic><bold>-value</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age in years (range)</td><td valign="top" align="center" rowspan="1" colspan="1">62.6 ± 11.6 (27–83)</td><td valign="top" align="center" rowspan="1" colspan="1">58.5 ± 9.1 (41–79)</td><td valign="top" align="center" rowspan="1" colspan="1">0.114</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Male</td><td valign="top" align="center" rowspan="1" colspan="1">21 (60.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (82.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.058</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Female</td><td valign="top" align="center" rowspan="1" colspan="1">14 (40.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (17.2%)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CE volume (cm<sup>3</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">37.6 ± 28.7</td><td valign="top" align="center" rowspan="1" colspan="1">22.9 ± 28.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FLAIR volume (cm<sup>3</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">109.4 ± 67.6</td><td valign="top" align="center" rowspan="1" colspan="1">83.4 ± 76.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.074</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>KPS</bold>, <italic><bold>n</bold></italic><bold>(%)</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&gt;70%</td><td valign="top" align="center" rowspan="1" colspan="1">6 (21.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (52.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.025</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Missing</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Extent of resection</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Gross-total</td><td valign="top" align="center" rowspan="1" colspan="1">11 (31.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (34.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Subtotal</td><td valign="top" align="center" rowspan="1" colspan="1">13 (37.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (48.3%)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Laser</td><td valign="top" align="center" rowspan="1" colspan="1">7 (20.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (3.5%)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Biopsy</td><td valign="top" align="center" rowspan="1" colspan="1">4 (11.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (13.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>MGMT status</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Methylated</td><td valign="top" align="center" rowspan="1" colspan="1">12 (37.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (52.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.297</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Non-methylated</td><td valign="top" align="center" rowspan="1" colspan="1">20 (62.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (48.0%)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Missing</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>IDH mutation</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Mutated</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Wild type</td><td valign="top" align="center" rowspan="1" colspan="1">34</td><td valign="top" align="center" rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Missing</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>EGFR amplification</bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Positive</td><td valign="top" align="center" rowspan="1" colspan="1">6 (30.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (63.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.056</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Negative</td><td valign="top" align="center" rowspan="1" colspan="1">14 (70.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (36.8%)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">   Missing</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Overall survival in days</td><td valign="top" align="center" rowspan="1" colspan="1">242.1 ± 118.0</td><td valign="top" align="center" rowspan="1" colspan="1">840.9 ± 372.6</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.00001</td></tr></tbody></table><table-wrap-foot><p><italic>STS, short-term survival (&lt;14.6 months); LTS, long-term survival (≥14.6 months); CE, contrast enhancement; FLAIR, fluid-attenuated inversion recovery; KPS, Karnofsky performance status; MGMT, methylguanine methyltransferase; IDH, isocitrate dehydrogenase; EGFR, epidermal growth factor receptor</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Patients' demographic, clinical, and molecular characteristics of patient population by group.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="center" colspan="4" style="border-bottom: thin solid #000000;">Summary of characteristics</th></tr><tr><th/><th valign="top" align="center">Short term survival (n=35)</th><th valign="top" align="center">Long term survival (n=29)</th><th valign="top" align="center">P-value</th></tr></thead><tbody><tr><td valign="top" align="left">Age in years (range)</td><td valign="top" align="center">62.6 ± 11.6 (27–83)</td><td valign="top" align="center">58.5 ± 9.1 (41–79)</td><td valign="top" align="center">0.114</td></tr><tr><td valign="top" align="left">Sex</td><td/><td/><td/></tr><tr><td valign="top" align="left">   Male</td><td valign="top" align="center">21 (60.0%)</td><td valign="top" align="center">24 (82.8%)</td><td valign="top" align="center">0.058</td></tr><tr><td valign="top" align="left">   Female</td><td valign="top" align="center">14 (40.0%)</td><td valign="top" align="center">5 (17.2%)</td><td/></tr><tr><td valign="top" align="left">CE volume (cm3)</td><td valign="top" align="center">37.6 ± 28.7</td><td valign="top" align="center">22.9 ± 28.7</td><td valign="top" align="center">0.004</td></tr><tr><td valign="top" align="left">FLAIR volume (cm3)</td><td valign="top" align="center">109.4 ± 67.6</td><td valign="top" align="center">83.4 ± 76.5</td><td valign="top" align="center">0.074</td></tr><tr><td valign="top" align="left">KPS, n(%)</td><td/><td/><td/></tr><tr><td valign="top" align="left">&gt;70%</td><td valign="top" align="center">6 (21.4%)</td><td valign="top" align="center">13 (52.0%)</td><td valign="top" align="center">0.025</td></tr><tr><td valign="top" align="left">Missing</td><td valign="top" align="center">7</td><td valign="top" align="center">4</td><td/></tr><tr><td valign="top" align="left">Extent of resection</td><td/><td/><td/></tr><tr><td valign="top" align="left">   Gross-total</td><td valign="top" align="center">11 (31.4%)</td><td valign="top" align="center">10 (34.5%)</td><td/></tr><tr><td valign="top" align="left">   Subtotal</td><td valign="top" align="center">13 (37.1%)</td><td valign="top" align="center">14 (48.3%)</td><td/></tr><tr><td valign="top" align="left">   Laser</td><td valign="top" align="center">7 (20.0%)</td><td valign="top" align="center">1 (3.5%)</td><td/></tr><tr><td valign="top" align="left">   Biopsy</td><td valign="top" align="center">4 (11.4%)</td><td valign="top" align="center">4 (13.8%)</td><td/></tr><tr><td valign="top" align="left">MGMT status</td><td/><td/><td/></tr><tr><td valign="top" align="left">   Methylated</td><td valign="top" align="center">12 (37.5%)</td><td valign="top" align="center">13 (52.0%)</td><td valign="top" align="center">0.297</td></tr><tr><td valign="top" align="left">   Non-methylated</td><td valign="top" align="center">20 (62.5%)</td><td valign="top" align="center">12 (48.0%)</td><td/></tr><tr><td valign="top" align="left">   Missing</td><td valign="top" align="center">3</td><td valign="top" align="center">4</td><td/></tr><tr><td valign="top" align="left">IDH mutation</td><td/><td/><td/></tr><tr><td valign="top" align="left">   Mutated</td><td valign="top" align="center">0</td><td valign="top" align="center">0</td><td/></tr><tr><td valign="top" align="left">   Wild type</td><td valign="top" align="center">34</td><td valign="top" align="center">29</td><td/></tr><tr><td valign="top" align="left">   Missing</td><td valign="top" align="center">1</td><td valign="top" align="center">0</td><td/></tr><tr><td valign="top" align="left">EGFR amplification</td><td/><td/><td/></tr><tr><td valign="top" align="left">   Positive</td><td valign="top" align="center">6 (30.0%)</td><td valign="top" align="center">12 (63.2%)</td><td valign="top" align="center">0.056</td></tr><tr><td valign="top" align="left">   Negative</td><td valign="top" align="center">14 (70.0%)</td><td valign="top" align="center">7 (36.8%)</td><td/></tr><tr><td valign="top" align="left">   Missing</td><td valign="top" align="center">15</td><td valign="top" align="center">10</td><td/></tr><tr><td valign="top" align="left">Overall survival in days</td><td valign="top" align="center">242.1 ± 118.0</td><td valign="top" align="center">840.9 ± 372.6</td><td valign="top" align="center">&lt;0.00001</td></tr></tbody></table></div>STS, short-term survival (&lt;14.6 months); LTS, long-term survival (≥14.6 months); CE, contrast enhancement; FLAIR, fluid-attenuated inversion recovery; KPS, Karnofsky performance status; MGMT, methylguanine methyltransferase; IDH, isocitrate dehydrogenase; EGFR, epidermal growth factor receptor.</transformed-table></extracted-table><extracted-table><table-id>T2</table-id><table-label>Table 2</table-label><table-caption>Classification performance summary of SVM classifier.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T2" position="float"><label>Table 2</label><caption><p>Classification performance summary of SVM classifier.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>SVM (LOO)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Accuracy</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Sensitivity</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Specificity</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>AUC</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold><italic>C</italic></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">STS vs. LTS</td><td valign="top" align="center" rowspan="1" colspan="1">71.88%</td><td valign="top" align="center" rowspan="1" colspan="1">77.14%</td><td valign="top" align="center" rowspan="1" colspan="1">65.52%</td><td valign="top" align="center" rowspan="1" colspan="1">0.752</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><p><italic>Regarding C, although we used the grid-search algorithm at the scale of c = 1:10 to optimize C, all selected C were 1</italic>.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Classification performance summary of SVM classifier.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left">SVM (LOO)</th><th valign="top" align="center">Accuracy</th><th valign="top" align="center">Sensitivity</th><th valign="top" align="center">Specificity</th><th valign="top" align="center">AUC</th><th valign="top" align="center">C</th></tr></thead><tbody><tr><td valign="top" align="left">STS vs. LTS</td><td valign="top" align="center">71.88%</td><td valign="top" align="center">77.14%</td><td valign="top" align="center">65.52%</td><td valign="top" align="center">0.752</td><td valign="top" align="center">1</td></tr></tbody></table></div>Regarding C, although we used the grid-search algorithm at the scale of c = 1:10 to optimize C, all selected C were 1.</transformed-table></extracted-table></extracted-tables-set>